P-glycoprotein (P-gp)

Overview

PGP, more commonly referred to as P-glycoprotein or P-gp, is a membrane-associated efflux transporter with major importance in pharmacology and disease biology. It is widely expressed in tissues and is known for its very broad substrate range, which gives it a substantial influence on the distribution of drugs between tissues. Because of this broad transport capacity, P-gp is a central determinant of absorption, tissue penetration, and elimination for many compounds.

Biologically, P-gp is especially important at barrier sites such as the blood-brain barrier (BBB), where it helps regulate the entry and clearance of endogenous molecules and xenobiotics. In the context of neurodegeneration, it has been studied as a key transporter involved in amyloid-β handling, including clearance of Aβ across the BBB. Its role in multidrug resistance is also well established in cancer research, where P-gp can reduce intracellular accumulation of therapeutic agents and thereby contribute to treatment failure.

Recent Publications Summary

Recent studies have continued to examine P-glycoprotein (P-gp) as both a mechanistic barrier to drug delivery and a therapeutic target for modulating tissue exposure. In a computational study, investigators developed a quantitative physicochemical model to predict P-gp substrate specificity and efflux ratio, aiming to move beyond simple substrate/non-substrate classification and provide quantitative estimates of P-gp-mediated efflux for drug discovery applications 42295475Jun. In parallel, a medicinal chemistry study of novel xanthene derivatives for Alzheimer’s disease found that several compounds increased P-gp activity, with compounds 5, 7, 9, 11, 12, and 16 showing the most significant activation; the authors also reported that P-gp was involved in the compounds’ ability to reverse amyloid-beta-induced cytotoxicity in SH-SY5Y cells 42380051Jun.

P-gp has also been explored in strategies to improve oral drug absorption and overcome multidrug resistance. Purine nucleoside-modified chitosan polymer micelles loaded with doxorubicin were designed to enhance intestinal uptake through nucleoside transporter mediation while simultaneously inhibiting P-gp efflux and CYP3A4 metabolism; these micelles achieved high drug loading, small particle size, and markedly increased oral bioavailability of doxorubicin in vivo 42289209Jun. Similarly, amino acid-based nanoparticles functionalized with quinidine were engineered for sequential delivery of a P-gp inhibitor followed by doxorubicin, with pH/glutathione-sensitive release enabling delayed drug exposure and strong antitumor activity against MDR EMT-6/AR1 cells 42036031Apr. In ovarian cancer, P-gp/ABCB1 was again implicated in adaptive resistance, with authors noting its influence on resistance to paclitaxel and olaparib and highlighting the need to better define niraparib resistance mechanisms 41998207Apr. Consistent with this theme, new anthrafuran derivatives were reported to circumvent Pgp-mediated multidrug resistance while retaining potent cytotoxicity against tumor cell lines 41905253Mar.

In neurological disease, P-gp was studied as a blood-brain barrier transporter relevant to amyloid-beta clearance and Alzheimer’s disease progression. Cu(ATSM) treatment in APP/PS1 mice restored brain microvascular P-gp abundance, reduced cortical human Aβ42 levels, and improved learning and long-term spatial memory, with a trend toward enhanced clearance of injected 125I-Aβ42 42216879May. Another study found that butyrate regulated blood-brain barrier transport and intraendothelial accumulation of Aβ peptides while evaluating P-gp expression alongside other BBB markers, supporting a role for transporter modulation in amyloid handling at the barrier 42166642May. Together, these reports reinforce P-gp as a key determinant of both therapeutic delivery and disease-relevant transport processes across the blood-brain barrier and in multidrug-resistant cancer 42216879May42166642May42036031Apr41905253Mar.

What Changes, What Holds

1. P-gp is becoming a quantitative, modelable efflux variable rather than only a binary substrate label
METHOD The computational work changes how P-gp is studied and predicted: instead of asking only whether a compound is transported, it aims to estimate efflux magnitude from physicochemical features 42295475Jun. The xanthene study also suggests P-gp activity can be pharmacologically increased in an Alzheimer’s context, but that is still an early mechanistic signal rather than a revision of the transporter’s established barrier role 42380051Jun.

2. P-gp remains a practical target for defeating oral delivery limits and multidrug resistance
REINFORCES These studies extend the established view that P-gp lowers intracellular drug exposure and can be therapeutically countered to improve tissue penetration and antitumor activity 42289209Jun42036031Apr. The new formulations do not alter what P-gp is understood to do; they strengthen the case that successful delivery systems must either bypass or inhibit its efflux function. The ovarian cancer and anthrafuran findings fit the same framework 41998207Apr41905253Mar.

3. Barrier P-gp modulation still looks relevant to amyloid handling and Alzheimer’s biology
REINFORCES The new work supports, rather than displaces, the established BBB role of P-gp in amyloid-β transport and clearance 42216879May42166642May. What changes is the therapeutic implication: restoring or tuning transporter abundance at the barrier may be a viable way to influence brain Aβ burden and cognition. The evidence is preclinical, so the key unresolved issue is whether these effects translate into durable human benefit.

Overview update candidates: quantitative prediction of P-gp efflux; P-gp activation as a potential Alzheimer’s-related mechanism; BBB transporter modulation as a therapeutic strategy for amyloid handling.